Title : The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.

Pub. Date : 2015 Dec

PMID : 26256674






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AIMS: Sirolimus is an mTOR inhibitor metabolized by CYP3A4 and CYP3A5. Sirolimus cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 The PBPK model developed based on CL(int) of recombinant CYP3A4, CYP3A5 and CYP2C8 predicted a small CYP3A5*3 effect on simulated sirolimus PK profiles. Sirolimus cytochrome P450 family 3 subfamily A member 4 Homo sapiens